Advocacy - Tax and Fiscal

Council Of State Bioscience Associations Letter on Orphan Drug Tax Credit – October 2017

October 31, 2017

The Honorable Paul Ryan
United States House of Representatives
H-232 The Capitol
Washington, DC 20515
The Honorable Kevin Brady
Committee on Ways & Means
1102 Longworth House Building
Washington, DC 20515

Dear Speaker Ryan and Chairman Brady:

As members of the Council of State Bioscience Associations (CSBA), we write to urge you to maintain the Orphan Drug Tax Credit (ODTC), which supports research into these devastating conditions, in the reformed tax code.

The CSBA is made up of state-based biotech organizations representing many of the companies developing treatments for a wide variety of rare diseases, ranging from rare pediatric cancers to deadly genetic disorders.

We support your efforts to reform America’s corporate tax code to make the U.S. competitive on the global stage, including your drive to lower the corporate tax rate.  However, paying for rate reduction by eliminating the ODTC would severely hamper our ability to bring life-saving treatments for rare and devastating diseases to patients.  Thus, we strongly support preserving the ODTC in any tax reform legislation.